Small Vessel Vasculitis

Similar documents
PAEDIATRIC VASCULITIS

ANCA associated vasculitis in China

Guideline on the clinical management of Henoch Schonlein Purpura (HSP)

HSP nephritis: when should you refer to a Nephrologist?

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

Managing Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge

Annual Rheumatology & Therapeutics Review for Organizations & Societies

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

Plasma exchanges in ANCA-associated vasculitis

SMALL TO MEDIUM VASCULITIS: RENAL ASPECT RATANA CHAWANASUNTORAPOJ UPDATE IN INTERNAL MEDICINE 2018

Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis

Henoch-Schonlein Purpura Guidelines

Henoch Schonlein Purpura

Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis

Glomerular pathology in systemic disease

Atlas of the Vasculitic Syndromes

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

TREATMENT OF ANCA-ASSOCIATED VASCULITIS

29th Annual Meeting of the Glomerular Disease Collaborative Network

AN OVERVIEW OF ANCA-ASSOCIATED VASCULITIS

ANCA-associated vasculitis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic

Rituximab treatment for ANCA-associated vasculitis in childhood

Index. Note: Page numbers of article titles are in boldface type.

A clinical syndrome, composed mainly of:

December 6, 2010 Asthma and Rheumatic Disorders and Vasculitis

Recent advances in management of Pulmonary Vasculitis. Dr Nita MB

Diagnostic Procedures for Vasculitis

Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward

Vasculitis Update. A selective review of what s new. Dr Jonathan Akikusa MBBS FRACP

Atypical IgA Nephropathy

Henöch Schönlein Purpura nephritis and management. Licia Peruzzi

HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT

anti-neutrophil cytoplasmic antibody, myeloperoxidase, microscopic polyangiitis, cyclophosphamide, corticosteroid

DIABETES MELLITUS. Kidney in systemic diseases. Slower the progression: Pathology: Patients with diabetes mellitus are prone to other renal diseases:

FAQ Identifying and enrolling participants

Year 2004 Paper one: Questions supplied by Megan

VASCULITIS. Case Presentation. Case Presentation

Renal involvement in vasculitis

EULAR/ERA-EDTA recommendations for the management of ANCAassociated

SCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND 2015

Vasculitis (Polyarteritis Nodosa, Microscopic Polyangiitis, Wegener s Granulomatosis, Henoch- Schönlein Purpura)

Small Vessel Vasculitis

Vasculitis Prof. Dr. med. Katharina Glatz Pathologie

EUVAS update June 5 th Marinka Twilt

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018

Review Article. Current concepts in Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis. Milind Aurangabadkar

RATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with

29 Glomerular disease: an overview

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

*HSP is a common vasculitis of small vessels with cutaneous & systemic complications. Its etiology is unknown& often follows URTIs.

Secondary IgA Nephropathy & HSP

ANCA+ VASCULITIDES CYCAZAREM,

Vasculitis local: systemic

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

Dhanalakshmi.R II yr MD Stanley medical college

The role of pathology in the diagnosis of systemic vasculitis

TREATMENT OF ANCA-ASSOCIATED VASCULITIS AN UPDATE. Loïc Guillevin. Hôpital Cochin, Université Paris Descartes. DU MALADIES SYSTEMIQUES, 7 March 2014

Case Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis

CUTANEOUS VASCULITIS. Katharine Warburton ST6 Dermatology

Prepared by Sarah Bozeman, MD, University of Mississippi Healthcare, and John Seyerle, Ohio State University

Dr Ian Roberts Oxford

GOODPASTURE'S SYNDROME WITH CONCOMITANT IMMUNE COMPLEX MIXED MEMBRANOUS AND PROLIFERATIVE GLOMERULONEFRITIS

Update and Review on Vasculitis. Ramona Raya, MD ACP Internal Medicine Congress August 7, 2015

Paediatric anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis: an update on renal management

Glomerular diseases mostly presenting with Nephritic syndrome

Protocol Version 2.0 Synopsis

ANCA-associated systemic vasculitis (AASV)

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

HENOCH SCHÖNLEIN PURPURA (VASCULAR PURPURA, ANAPHYLACTOID PURPURA) IN CHILDREN Single choice tests (SC)

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: A study of 126 cases

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Year In Review: VasculitisPers. Disclosures. Learning Objectives. none 4/16/2018. Describe new medications for the treatment of vasculitis

Case Report Treatment of Complicated Henoch-Schönlein Purpura with Mycophenolate Mofetil: A Retrospective Case Series Report

Vasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi

CHAPTER 4. Paediatric Renal Biopsies

Clinical Commissioning Policy: Rituximab For ANCA Vasculitis. December Reference : NHSCB/ A3C/1a

RARE JUVENILE PRIMARY SYSTEMIC VASCULITIS

Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study

Case Rep Nephrol Urol 2013;3: DOI: / Published online: January 27, 2013

GRANULOMATOSIS WITH POLYANGIITIS

Crescentic Glomerulonephritis (RPGN)

Vasculitis local: systemic

Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease

Objectives. Glomerular Diseases. Glomerulonephritis. Microscopic Hematuria 11/6/2016. Discuss diagnosis of glomerular diseases

Clinical Case Conference Tuesday August 25, 2015 Dana Assis, MD

Immune-mediated lung disease. Ian Sabroe

Nephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba

Antineutrophil cytoplasm antibody associated vasculitis: recent developments

Joint Trust Guideline for the Management of: Henoch Schönlein Purpura (HSP) in Children

THE URINARY SYSTEM. The cases we will cover are:

THE URINARY SYSTEM. The cases we will cover are:

4. KIDNEYS AND AUTOIMMUNE DISEASE

VASCULITIS AND VASCULOPATHY

Renal mani f e s t a t ions o f Henoch Schönlein pur pur a in a 6-month prospective study of 223 children

C1q nephropathy the Diverse Disease

Vasculitis of the peripheral nervous system

Elevated Serum Creatinine, a simplified approach

IgA Nephropathy - «Maladie de Berger»

LRI Children s Hospital

Transcription:

Small Vessel Vasculitis Paul A Brogan Professor of Vasculitis and Consultant Paediatric Rheumatologist Department of Rheumatology Institute of Child Health and Great Ormond St Hospital, London UK P.brogan@ucl.ac.uk

Chapel Hill Consensus definitions of vasculitis 2012 Jennette et al Arthritis Rheum. 2013 Jan; 65(1):1-11

Overview HSP (IgA Vasculitis) ANCA associated vasculitides (AAV)

HSP IgA Vasculitis

HSP classification criteria [Ozen S et al 2010, Ann Rheum Dis. 2010;69:798-806.] Purpura, predominantly lower limb OR diffuse* (mandatory) PLUS 1 out of 4 of: 1. abdo pain 2. IgA on biopsy 3. haematuria/proteinuria 4. arthritis/arthralgia *If diffuse (ie atypical distribution) then IgA deposition on biopsy required Sn 100% Sp 87%

Epidemiology: UK Incidence is estimated at 20.4 per 100,000 children in the UK Indian subcontinent: 24 per 100, 000 White Caucasians: 17.8 per 100,000 Afro-Caribbean: 6.2 per 100,000 Peak onset age 4 to 5 years of age, M>F Higher incidence during winter and the early spring

Pathogenesis nature and nurture Lau KK et al. Ped Neph 2010:25:19-26

Infection polymeric Gd-IgA1 Anti glycan IgG or IgA1 bind Gd-IgA Immune complexes IgA1-IgG, IgA1-IgA1, complement Glomerular injury

Main clinical features Palpable purpura Arthritis or arthralgia Abdominal pain Gastrointestinal haemorrhage Glomerulonephritis

Other features Intussusception Pancreatitis Pulmonary disease with haemorrhage Orchitis CNS involvement fits and coma Ureteric obstruction Parotitis Carditis Guillain-Barre syndrome

Bullous HSP Kausar S et al Journal of Dermatological Treatment. 2009; 20:88 90

Koné-Paut I: http://www.pedrheumonlinejournal.org/jan-feb05/henoch_schoelein.htm

HSP: Cerebral vasculitis Bakkaloglu, S. A. et al. Nephrol. Dial. Transplant. 2000 15:246-248

Vascular deposition of IgA

HSP nephritis Focal and segmental proliferative glomerulonephritis 20-61% of HSP patients, depending on criteria for definition of nephritis Normally manifest between a few days and a few weeks after clinical presentation, but can occur up to 2 months or (rarely) more from presentation

Who needs a renal biopsy? 1. Nephritic/nephrotic presentation (urgent) 2. Raised creatinine, hypertension or oliguria (urgent) 3. Heavy proteinuria (Ua:Ucr persistently >100 mg/mmol) on an early morning urine sample at 4 weeks. Serum albumin not necessarily in the nephrotic range. 4. Persistent proteinuria (not declining) after 4 weeks?

HSP Treatment Supportive Steroids do not prevent nephritis For severe HSPN: lack of evidence base Individualised: steroids, CYC, MMF, AZA, plasma exchange, others Zaffanello M, Fanos V (2009) Treatment-based literature of Henoch- Schönlein purpura nephritis in childhood. Pediatr Nephrol. 24:1901 1911

HSPN: Rx based on severity RPGN: (>50% crescents) aggressive therapy with corticosteroid, cyclophosphamide and possibly plasma exchange Severe nephritis but not rapidly progressive (<50% crescents): Corticosteroids alone or in combination with CYC, AZA, MMF, others Persistent proteinuria: ACEI Zaffanello M, Fanos V, 2009

Indication for steroid in non-renal HSP: personal practice Severe haemorrhagic oedema affecting the face or scrotum Severe bullous HSP Testicular involvement Severe gastrointestinal symptoms, particularly abdominal pain and gastrointestinal bleeding Other severe systemic manifestation: pulmonary haemorrhage; cerebral vasculitis, pancreatitis etc

HSP outcome Benign But significant morbidity associated with cutaneous and gastrointestinal disease in short term and renal disease in the long term

Poorer renal prognosis Nephrotic syndrome Nephritic and nephrotic syndrome 20% of patients with acute mixed nephritic and nephrotic syndrome progressed to end stage renal failure 44 to 50% develop hypertension or chronic kidney disease Older children (>7 yrs) and adults

Duration of clinical features 1/3 of children have symptoms for less than 14 days 1/3 for 2-4 weeks 1/3 greater than 4 weeks Recurrence of symptoms occurs in around 1/3 of cases, generally within four months of resolution of the original symptoms. Recurrences are more frequent in those with renal involvement.

Long term renal involvement in HSP Narchi et al 2005. ADC, 90:916-920 1133 children (12 studies) Renal involvement 34% 80% isolated haematuria/proteinuria 20% nephritis or nephrotic syndrome Renal involvement occurred by 4 weeks in 85% Persistent renal involvement in 1.8%

ANCA associated vasculitides Granulomatosis with polyangiitis (GPA) (formerly Wegener s granulomatosis) Microscopic polyangiitis (MPA) Eosinophilic Granulomatosis with polyangiitis (EGPA; formerly Churg Strauss Syndrome)

ANCA canca PR3-ANCA panca MPO-ANCA

How do ANCA cause vasculitis?

How do ANCA cause vascular TNF- LPS injury?

Why do patients develop ANCA? Nature and nurture

GWAS Type of ANCA more closely linked to genetics rather than clinical phenotype Lyons PR3-ANCA: et al; NEJM 2012 HLADP; SERPINA1; PRTN3 MPO-ANCA: HLADQ

Granulomatosis with polyangiitis (Wegener s granulomatosis)

GPA (Wegener s granulomatosis) [2010, Ozen S et al ARD] At least 3 out of 6 of the following criteria: 1. histopathology 2. upper airway involvement 3. laryngo-tracheobronchial stenoses 4. pulmonary involvement 5. ANCA positivity 6. renal involvement Sn 93.3% Sp 99.2%

Segmental left main bronchus stenosis A B

WG: lung

MPA

Microscopic polyangiitis Necrotizing SVV with few or no immune deposits Pulmonary capillaritis and glomerulonephritis (rapidly progressive renal failure) But any organ can be affected panca; MPO-ANCA Renal Limited form (but watch out for other organ involvement)

Microscopic polyangiitis: alveolar haemorrhage

MPA: glomerulus

Microscopic polyangiitis (MPO- ANCA) A 9A: Resected colon taken from a 13-year-old girl with microscopic polyangiitis (initially regarded clinically as renal limited vasculitis; MPO ANCA positive), and severe renal failure due to crescentic nephritis. Torrential gastrointestinal haemorrhage was the result of vasculitis affecting the colon, and a vasculitic ulcer is depicted. 9B: Magnetic resonance angiography (MRA) of the brain performed following acute visual loss in a 12 year old previously well female, with MPO ANCA positivity, but normal renal function. Multiple parieto-occipital haematomas are depicted. The intra and extra-cranial t large and medium-sized arteries were normal, and the final diagnosis was MPO ANCA positive small vessel vasculitis of the brain. B

Churg Strauss Syndrome

CSS Eosinophil rich and granulomatous inflammation, esp. of respiratory tract Necrotizing vasculitis of small and (possibly) medium vessels Associated with asthma and hypereosinophilia MPO-ANCA positivity

CSS in kids: n=32 Zwerina et al 2008 All patients had significant eosinophilia and asthma Histological evidence of eosinophilia and/or vasculitis was present in virtually all patients ANCA were found in only 25%

ANCA to monitor disease activity and guide Rx?

Treatment

Standard treatment of AAV in children: induction/maintenance Induction: Corticosteroids PLUS CYC (+/-PE) PLUS Antiplatelet agent Maintenance: Low dose corticosteroid; AZA, MMF, other Rituximab: induction and/or maintenance

AAV outcome in children GPA: 40% develop renal failure; 12% mortality MPA: mortality 0-14% EGPA: mortality 18%

SHARE guidelines http://www.printo.it/share Oxford Handbook of Paediatric Rheumatology http://www.vasculitis.org.uk/professionals/paediatric-vasculitis-guidelines